Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/9/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mary Fitzgerald?

Mary F. Fitzgerald

Executive Vice President of Respiratory

Pulmagen Therapeutics Limited

Direct Phone: +44 **** ******direct phone

Email: m***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Pulmagen Therapeutics Limited

Japan

Company Description

Pulmagen Therapeutics is a privately held respiratory drug development company headquartered in Burnham, Bucks, UK. The company has developed a portfolio of clinical programmes targeting chronic respiratory diseases including severe persistent asthma, allerg... more

Find other employees at this company (5)

Background Information

Employment History

Pieris Pharmaceuticals Inc


Head of Pharmacology

Bayer HealthCare AG


Vice President Respiratory Medicine

Pieris Pharmaceuticals, Inc.


Cso

Calcico Therapeutics Limited


Director and Executive Vice President Respiratory

Argenta Discovery Limited


Affiliations

Pulmatrix Inc

Scientific Advisory Board Member


Education

BSc

Pharmacology

Bath University


Ph.D.


PhD

Sunderland University


Web References(25 Total References)


Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)

www.pieris.com [cached]

Mary Fitzgerald, Ph.D.
Mary Fitzgerald, Ph.D. Vice President of Respiratory Medicine Dr. Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.


Pulmagen Therapeutics | www.pulmagen.com | Oral & Inhaled medicines for chronic lung disease

www.pulmagen.com [cached]

Dr Mary Fitzgerald - Executive VP, Respiratory
Mary Fitzgerald Formerly Director and Executive VP Respiratory of Argenta Discovery Limited and Director of Etiologics Limited. Previously with Bayer Healthcare for 14 years, latterly as Head of Pharmacology. Mary has spent over 25 years conducting research and development into drugs for the treatment of respiratory disease.


Pulmatrix

www.pulmatrix.com [cached]

Mary Fitzgerald, PhD
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. In this position she has had oversight for two Phase II and 3 Phase I studies and has built up a network of leading clinical respiratory consultants including Professor Neil Barnes, Dr Dave Singh and Professor Peter Calverley. Considered one of the world leaders in drug development for COPD and in the preclinical models for respiratory disease, Dr. Fitzgerald has been a Director of Argenta/Pulmagen since October 2004. She has been responsible for clinical development at Argenta and more recently at Pulmagen Therapeutics since 2008. Since 2002, she has also been Director of and is a founding member of Etiologics Limited. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She has spent over 20 years conducting research into chronic respiratory disease. She was the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease.


www.smi-online.co.uk

Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.


www.smi-online.co.uk

Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory